Macclesfield-based medical research company, Illingworth Research Group, continues to go from strength to strength with almost 100 per cent growth in 2019, and local MP, David Rutley, visited its premises in the town recently, to discuss future growth opportunities for the company.
Founded in 1998 by longstanding Chief Executive, John Illingworth, and currently employing well over 100 people across its sites in the UK, US, Europe and Australia in addition to over 500 research nurses in over 45 countries, the company is a market leader in providing on and off-site research nursing, patient concierge, medical photography and clinical trial solutions for much-needed and important clinical trials, often involving rare or specialised conditions. On his visit to the company's headquarters in Park Green, David was joined by Mr Illingworth and met with his senior leadership team, as well as being given a tour of the premises.
Mr Illingworth explained that the company partners with a broad range of industries, including the pharmaceutical, healthcare, biotechnology and medical device sectors. David was impressed to learn that the company has a clear international as well as domestic focus, operating in 46 countries around the world, with over 1,100 nursing visits in 2019. The company's wide geographic footprint makes the mobile nature of its nurses essential, as, often, those patients with rare diseases who would benefit from participating in clinical trials are widely dispersed. By using mobile nurses, the company can reach more people and help make a greater difference to the lives of patients, and their families and follows the company’s vision to be the best patient focussed solutions company for clinical trials worldwide.
David was pleased to learn from Mr Illingworth that the company is looking to expand further into new markets, and David gave his support in working with the company to help it achieve these goals in the months ahead. David was also pleased that the company is looking to expand its apprenticeships offer throughout this year.
Speaking after his visit, David said, "Illingworth Research Group undertakes vital work in supporting important clinical trials, making a crucial difference in helping to improve our understanding of a range of often serious medical conditions and enabling progress towards developing cures for them. It was good to hear that the business is thriving and looking to expand and grow further in the future. I will continue to support the company and its hard-working staff as it takes forward these objectives."